Background and Objective Tacrolimus is an immunosuppressive drug used for the prevention of the allograft rejection in kidney transplant recipients. It exhibits a narrow therapeutic index and large pharmacokinetic variability. Tacrolimus is mainly metabolized by cytochrome P450 (CYP) 3A4 and 3A5 and effluxed via ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), encoded by ABCB1 gene. The influence of CYP3A5*3 on the pharmacokinetics of tacrolimus has been well characterized. On the other hand, the contribution of polymorphisms in other genes is controversial. In addition, the involvement of other efflux transporters than P-gp in tacrolimus disposition is uncertain. The present study was designed to investigate the effects of genetic polymorphisms of CYP3As and efflux transporters on the pharmacokinetics of tacrolimus. Subjects and Methods A total of 500 blood concentrations of tacrolimus from 102 adult stable kidney transplant recipients were included in the analyses. Genetic polymorphisms in CYP3A4 and CYP3A5 genes were determined. In addition, the genes of efflux transporters including P-gp (ABCB1), multidrug resistance-associated protein (MRP2/ABCC2) and breast cancer resistance protein (BCRP/ABCG2) were genotyped. For ABCC2 gene, haplotypes were determined as follows:
rejection in solid organ transplant recipients [1] . Tacrolimus exhibits a narrow therapeutic index and considerable interindividual pharmacokinetic variability [2] . Therefore, routine therapeutic drug monitoring is an integral part of tacrolimus immunosuppressive therapy [3] .
Tacrolimus is extensively metabolized by cytochrome P450 (CYP) 3A4 and 3A5 in the liver and small intestine [4, 5] . In addition, it is a substrate of P-glycoprotein (P-gp), encoded by multidrug resistance (MDR) 1/ABCB1 gene [6] . Pharmacogenetic studies indicate that the interindividual variability in tacrolimus pharmacokinetics can be partly related to genetic polymorphisms in CYP3A and ABCB1 genes [7] . Among them, the most frequently investigated polymorphism is CYP3A5*3 (6986A[G, rs776746), which causes an alternative splicing and is associated with low levels of CYP3A5 functional protein [8, 9] . CYP3A5 expressers, who carried at least one CYP3A5*1 (wild type) allele, showed a lower dose-adjusted tacrolimus concentration and a higher dose requirement compared to CYP3A5 nonexpressers (CYP3A5*3 homozygotes) [7] . Several population pharmacokinetic analyses have demonstrated that CYP3A5*3 had a significant impact on the apparent clearance of tacrolimus [10, 11] .
Accumulating evidence indicates that in the small intestine, CYPs and efflux transporters, mainly CYP3A and P-gp, cooperatively function as the absorption barrier [12] . Using the pig intestinal mucosa in an Ussing chamber, Lampen et al. [13] have demonstrated that when tacrolimus is added to the luminal side of the intestinal preparation, more than 90 % of the metabolites are transported from the tissue back into the luminal chamber, most likely by active transport. The concentrations of tacrolimus were more than 100-fold higher than the concentrations of the formed metabolites, and these findings suggested that the metabolites of tacrolimus either have a higher affinity for the P-gp than the parent or are substrates of a different transporter [12] . In the small intestine, multidrug resistanceassociated protein 2 (MRP2: encoded by ABCC2 gene) and breast cancer resistance protein (BCRP: encoded by ABCG2 gene) as well as P-gp play an important role in the efflux of xenobiotics [14] . Compared to ABCB1 polymorphisms, the information on the association between the pharmacokinetics of tacrolimus and polymorphisms in ABCC2 and ABCG2 genes is limited. Therefore, in this study, the effects of polymorphisms in CYP3A4, CYP3A5, ABCB1, ABCC2 and ABCG2 genes on the dose-normalized concentration of tacrolimus were investigated in adult stable kidney transplant recipients. Furthermore, using a population pharmacokinetic approach, we examined whether these polymorphisms can account for the interindividual variability in the population pharmacokinetic parameters of tacrolimus.
Methods

Patients
The study protocol was reviewed and approved by the Institutional Review Board at Rhode Island Hospital (IRB#0159-03, 0054-05, 0066-06, 4060-10 and 4176-10), and all patients gave informed consent to participate. Patients were excluded if they were suffering from severe liver dysfunction, were pregnant, nursing or younger than 18 years of age. In addition, patients with pancreatic transplantation were excluded from the study. In total, 102 adult stable kidney transplant recipients were included in this study. Detailed demographic information is presented in Table 1 . All study participants received triple immunosuppressive drug regimens including tacrolimus oral tablets Values are expressed as median (range) unless specified otherwise a Creatinine clearance was estimated using Cockcroft-Gault formula (Prograf, Astellas Pharma US Inc., Northbrook, IL, USA), prednisone and mycophenolic acid.
Pharmacokinetic Study
On the day of pharmacokinetic study, subjects underwent routine physical examination including blood pressure, height and weight measurement. After collecting the predose (trough) blood sample (4.0 mL) into ethylenediaminetetraacetic acid (EDTA) vacutainers (Becton Dickinson, Franklin Lakes, NJ, USA), immunosuppressive drugs were administered. Blood samples (0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose) were then collected up to 12 h from 31 patients, whereas two blood samples (pre-dose and 2-h postdose) were collected from 71 patients. We have selected 0 and 2 h post dose because trough concentration usually reflects the elimination phase, whereas the concentration at 2 h post dose, although it is not monitored, is around the absorption phase of the drug. The whole blood samples were immediately stored at -80°C until further analysis.
Bioanalytical Assay
Quantitative analysis of tacrolimus was performed using a previously published and utilized assay using an Agilent 1100 Series HPLC system (Agilent Technologies, Santa Clara, CA, USA) coupled to an API 4000 tandem mass spectroscopy system (AB Sciex, Foster City, CA, USA) equipped with a turbo electrospray ion source [15] . In brief, sample preparation involved the addition of 800 lL of ZnSO 4 (17.28 g/L): methanol (30:70, v/v) containing the internal standard (ascomycin, 100 ng/mL) to a 200 lL aliquot of EDTA anticoagulated whole blood, calibration standards or quality control samples. Samples were vortex mixed and centrifuged (13,000 rpm for 10 min at 4°C), and 50 lL of supernatant was injected onto an HPLC column (4.6 9 150 mm, 3.5 lm, Eclipse Zorbax XDB-C8, Agilent Technologies) maintained at 65°C. The mobile phase that consisted of (A) HPLC grade methanol with 0.1 % v/v formic acid and (B) 0.1 % v/v formic acid was pumped at a flow rate of 1.0 mL/min. The mass spectrometer was run in the single ion mode and focused on the [M ? Na] ? of tacrolimus and ascomycin (internal standard). The lower limit of quantification for tacrolimus in human EDTA whole blood was at 62.5 pg/mL, and the range of reliable response was from 62.5 pg/mL to 25.0 ng/mL. Inter-day accuracies for tacrolimus were within 85-115 %, and total imprecision was \15 %.
Genotyping of CYP3A4, CYP3A5, ABCB1, ABCC2
and ABCG2 Genes Genomic DNA from patients' peripheral blood samples was extracted using QIAamp DNA Mini Kit (Qiagen, Genetic Analyzer (Life Technologies). The primers for the amplification of CYP3A4 gene were described previously [16] . ABCC2 haplotypes were determined using Haploview version 4.1 [17] .
Data Analysis
Statistical analysis was carried out using the SPSS software (version 19.0, SPSS Inc., Chicago, IL, USA) and GraphPad Prism (version 4.0, GraphPad Software, Inc., La Jolla, CA, USA). Normal distribution of log-transformed tacrolimus concentration was verified using the Shapiro-Wilk test, and the significance level was tested using independent samples t test or analysis of variance (ANOVA) followed by Bonferroni correction. Comparisons of tacrolimus dose were carried out using the Mann-Whitney U test or KruskalWallis test followed by Dunn's test.
Population pharmacokinetic modeling was performed using nonlinear mixed effects modeling with NONMEM (version 7.2.0, ICON Development Solutions, Ellicott City, MD, USA). PLT Tools (P Less Than, San Francisco, CA, USA) was used as an interface for NONMEM. Doubleprecision, first-order conditional estimation (FOCE) with interaction and subroutines ADVAN4 TRANS4 were used. The model selection was based on goodness-of-fit criteria, including diagnostic plots, minimum objective function value (MOFV) after accounting for the number of fitted parameters, precision and the physiological plausibility of the estimates. The inter-subject variability in the pharmacokinetic parameters was modeled assuming an exponential distribution. Additive, proportional and combined proportional and additive models were investigated, but a proportional error model best described the variability in the data.
Covariates (sex, ethnicity, diabetes mellitus, age, weight, time post-transplantation, hematocrit, hemoglobin A1c, glucose, alanine aminotransferase, alkaline phosphatase, albumin, total bilirubin, blood urea nitrogen, creatinine, creatinine clearance, concomitant prednisone dose, concomitant mycophenolic acid dose and genetic polymorphisms) were examined graphically via plots of g vs. covariate values, where g is the individual random effect with a mean of 0 and a variance of x 2 . The candidate covariates identified during graphical screening were then tested in NONMEM. The influence of continuous covariates on the pharmacokinetic parameters was modeled according to a power model scaled to the population median covariate value. The influence of categorical covariates on the pharmacokinetic parameters was modeled using a proportional relationship.
The statistical significance of the covariates was assessed using a likelihood ratio test corresponding to a decrease in MOFV of [3.84 (with one degree of freedom: p \ 0.05) in comparisons between two hierarchical models. These covariates were then included in the basic population model using the forward stepwise method until objective function no longer improved. A covariate was retained in the model if the objective function changed by 6.63 or greater (p \ 0.01) when it was removed from the full model. This was repeated and continued until all remaining covariates were significant in the final model.
The predictability of the final model was evaluated using a visual predictive check. Data for 1,000 data sets were simulated and compared with the observed data set. Within the 2.5th and 97.5th percentiles of the simulated concentration, a 95 % prediction interval was constructed and plotted along with the observed data and the median of the simulated concentration. A bootstrap procedure was performed to determine the stability and robustness of the final model. A thousand bootstrap re-samples of the original data set were created, and these were evaluated using the final model.
Results
Patients' Characteristics
Demographic characteristics, doses of immunosuppressive agents and biochemical indices of study participants are presented in Table 1 . None of the study subjects were administered drugs that are known to inhibit or induce tacrolimus disposition.
Effects of Genetic Polymorphisms on C 0 and C 2 of Tacrolimus
Allele frequencies of genetic polymorphisms in CYP3A4, CYP3A5, ABCB1, ABCC2 and ABCG2 genes are shown in Table 2 . We investigated the effects of these polymorphisms on dose-normalized tacrolimus concentrations at pre-dose (C 0 /dose) and 2-h post dose (C 2 /dose) ( [18] . Therefore, in the following study, the patients were divided into three groups according to ABCC2 haplotypes as follows: MRP2 high-activity group (H2/H2 and H1/H2), MRP2 low-activity group (H9/H9, H12/H12, H1/H9 and H1/H12) and MRP2 reference group (H1/H1, H2/H9 and H2/H12). The tacrolimus C 0 /dose and C 2 /dose in the MRP2 high-activity group were 1.54-fold and 1.80-fold lower than those in the MRP2 low-activity group and reference group (p = 0.007 and p \ 0.001, respectively, Table 3 ). There were no significant differences in the concentrations between the MRP2 low-activity group and reference group. These results suggest that 1249G[A but not 3972C[T has a significant effect on the dose-normalized tacrolimus concentration. In CYP3A4*1B carriers, CYP3A5 expressers or the MRP2 high-activity group, significantly higher tacrolimus doses were required compared to the other group, respectively (Table 3 ).
Combined Effects of CYP3A5*1 and ABCC2
Haplotype on C 0 and C 2 of Tacrolimus
To investigate the combined effects of CYP3A5*1 and ABCC2 haplotype on C 0 /dose and C 2 /dose of tacrolimus, the patients were divided into four groups with respect to CYP3A5 expressers or non-expressers and MRP2 highactivity group or low-activity and reference group. CYP3A5 expressers with MRP2 high-activity group showed a significantly lower C 0 /dose and C 2 /dose of tacrolimus compared to the other three groups (CYP3A5 expressers with MRP2 low-activity ? reference group, CYP3A5 non-expressers with MRP2 high-activity group, CYP3A5 non-expressers with MRP2 low-activity ? reference group) (Fig. 1a, b) . The tacrolimus dose in CYP3A5 expressers with MRP2 high-activity group was significantly higher than that in CYP3A5 non-expressers with MRP2 high-activity group or MRP2 low-activity ? reference group (Fig. 1c) .
Population Pharmacokinetics of Tacrolimus
To understand the relative impacts of these polymorphisms on the pharmacokinetics of tacrolimus, population pharmacokinetic analysis was carried out. The pharmacokinetics of tacrolimus was best described using a twocompartment model with first order absorption and an During the preliminary covariate screening (univariate analysis), CYP3A5 expressers, CYP3A4*1B carriers, MRP2 high-activity group, being Caucasian and age were found to be significant covariates for CL/F (Table 5) . We have previously reported slightly longer tacrolimus T max (time to reach the maximum blood concentration following , where CYP3A5 = 0 for CYP3A5 non-expressers; CYP3A5 = 1 for CYP3A5 expressers; MRP2 = 0 for MRP2 low-activity ? reference group; MRP2 = 1 for MRP2 high-activity group. The parameters of the final model, including bootstrap medians and 95 % confidence intervals for the pharmacokinetic parameters, are presented in Table 6 . Interindividual variability for V 1 /F and proportional error in the final model were 157 and 18 %, respectively. Figures 2 and 3 present goodness-of-fit plots for the final model, and the visual predictive check for tacrolimus dose-normalized concentration, respectively. The visual predictive check (Fig. 3) supports the finding that ABCC2 haplotype as well as CYP3A5 polymorphism significantly affected the pharmacokinetics of tacrolimus. 
Discussion
In the present study, it is demonstrated that genetic polymorphisms of CYP3A5 and ABCC2 affect the pharmacokinetics of tacrolimus. Dose-normalized tacrolimus concentration was 2.3-fold lower in CYP3A5 expressers than in CYP3A5 non-expressers. In addition, the population pharmacokinetic model showed that CL/F was twofold higher in CYP3A5 expressers than in CYP3A5 nonexpressers. There are numerous reports on a strong relationship between CYP3A5 polymorphism and tacrolimus pharmacokinetics in kidney, heart and liver transplant recipients [7] , which are consistent with the finding of the present study. Patients with MRP2 high activity, who are the homozygote of H2 (1249G[A) and the heterozygote of H2 and H1 (wild type), showed a significantly lower dosenormalized concentration of tacrolimus compared to the MRP2 low-activity group and reference group. Furthermore, the MRP2 high-activity group was an independent covariate for CL/F of tacrolimus. Although 3972C[T had a significant effect on the dose-normalized concentration of tacrolimus, haplotype analysis demonstrated that there is no difference in tacrolimus pharmacokinetics between the reference group and MRP2 low-activity group, which included 3972C[T. This is probably due to the linkage disequilibrium in ABCC2 gene: 81 % (30 out of 37) of the patient population that has at least one 1249G[A did not have 3972C[T. These results suggest that ABCC2 haplotypes, not each individual polymorphism, should be taken into account when characterizing the effects of ABCC2 polymorphisms on tacrolimus pharmacokinetics. According to the routine practice of our transplant center, tacrolimus doses are optimized to achieve a blood concentration of 10-12 ng/mL for the first 6 months and 4-6 ng/mL thereafter. CYP3A5 expressers have been reported to show a higher dose requirement compared to CYP3A5 non-expressers [7] , which is in accordance with our findings. Among CYP3A5 expressers, the tacrolimus dose in the MRP2 high-activity group had the tendency to increase compared with the MRP2 low-activity and reference group, although there was no significant difference [median (25th-75th percentiles): 11.0 mg (8.5-12.0) and 6.0 mg (5.0-9.5), respectively]. This finding suggests that characterization of the ABCC2 haplotype as well as CYP3A5 genotype may be informative for adjusting the tacrolimus dose in the early postoperative period. To evaluate the usefulness of ABCC2 haplotypes in the dose adjustment of tacrolimus, further studies using much larger sample sizes are needed. This is the first report on the significant influence of ABCC2 polymorphism on the pharmacokinetics of tacrolimus. The association between ABCC2 polymorphism and tacrolimus concentrations was reported in only two studies in transplant recipients in Europe [11, 21] . A population pharmacokinetic approach of tacrolimus in pediatric transplant recipients did not identify ABCC2 polymorphism as a significant covariate [11] . Renders et al. [21] , in adult transplant recipients, found a combined effect of ABCC2 -24C[T and 1249G[A on tacrolimus trough concentration, although there were no influences of individual ABCC2 polymorphisms. The discrepancies between the present study and the previous studies could be because of the difference in the environmental factor or the ratio of ethnic groups and diabetes among the transplant recipients. Further studies are needed to confirm the effects of ABCC2 polymorphisms on the tacrolimus disposition.
The mechanism underlying the effect of the ABCC2 haplotype on tacrolimus pharmacokinetics is not known. It was recently shown that erythromycin is a substrate for human MRP2 [22, 23] . Erythromycin is another macrolide lactone with comparable physicochemical properties to tacrolimus (molecular weight, LogP, topological polar surface area). The metabolism of erythromycin via CYP3A4 was increased in Mrp2 knockout mice and human carrying ABCC2 -24C[T, suggesting the interplay between the metabolism and MRP2 [23] . It was suggested that the metabolites of tacrolimus are substrates of other transporters than P-gp [12] . We hypothesize that tacrolimus metabolites or tacrolimus is a substrates for MRP2. Thus, MRP2 may be involved in the clearance of tacrolimus in cooperation with CYP3A in the small intestine. Further in vitro studies are warranted to elucidate the transport of tacrolimus and its metabolites via MRP2.
Although CYP3A4*1B significantly reduced the dosenormalized tacrolimus concentration, CYP3A4*1B was not the covariate for any parameters in the population pharmacokinetic model. This could be because of a possible linkage between CYP3A4*1B and CYP3A5*1. In this study, we observed that 81 % of the patient population that express at least one CYP3A4*1B allele is also expressing a functional CYP3A5. Our finding that CYP3A4*1B does not have an independent effect on tacrolimus pharmacokinetics is consistent with the previous result [24] . Elens et al. [25] have reported that CYP3A4*22 was associated with reduced tacrolimus clearance. In this study, a dose-normalized concentration of tacrolimus in CYP3A4*1/*22 had the tendency to increase compared with CYP3A4*1/*1, but this difference was not significant. This might be because the allele frequency of CYP3A4*22 is low and our sample size (n = 102) was not large enough to evaluate the effect of CYP3A4*22 on the pharmacokinetics of tacrolimus. There were no linkages between CYP3A4*22 and CYP3A5*1 or CYP3A4*1B. Further studies are needed to elucidate the contribution of CYP3A4*22 to the disposition of tacrolimus. ABCB1 1236C[T, 2677G[T, A and 3435C[T and ABCG2 421C[A had no effect on the dosenormalized concentration and any population pharmacokinetic parameters of tacrolimus in this study. Influences of ABCB1 polymorphisms on the pharmacokinetics of tacrolimus are still controversial, but most studies have failed to find an association between them [7] . The frequencies of most SNPs except for CYP3A4*1B and CYP3A5*3 perfectly agree with those predicted by the Hardy-Weinberg equation. As for CYP3A5*3, the Hardy-Weinberg equation predicts *1/*1: n = 3 (observed: n = 8), *1/*3: n = 28 (observed: n = 18), *3/*3: n = 71 (observed: n = 76). This discrepancy is because there is an ethnic difference in the allele frequency of CYP3A5*3 (Caucasian: 91.1 %; Hispanic: 75.0 %; African-American: 45.5 %) and because the ratios of ethnic groups were different in our population (73 Caucasian, 14 Hispanic, 11 African-American, 4 others).
The values of the population pharmacokinetic parameters of tacrolimus in this study are comparable to the values reported previously [26] [27] [28] [29] . Age was also identified as a covariate for CL/F, and the model demonstrated that the apparent clearance of tacrolimus decreases with age. Older age is reported to be associated with a higher tacrolimus dose-normalized concentration or lower tacrolimus dose requirement [30] [31] [32] , which is in accordance with our finding. Diabetes significantly reduced the objective function by 12.96 as a covariate for an absorption lag time. Patients with long-term diabetes exhibit delayed gastric emptying because of diabetes-induced autonomic neuropathy, which may affect the rate of drug absorption [20] . This result supports the longer T max of tacrolimus in diabetic patients [19] .
Similar to cyclosporine, tacrolimus is highly bound to red blood cells, and the reduced binding to blood cells or plasma proteins increases the values of unbound fraction and apparent clearance [33, 34] . Tacrolimus apparent clearance was higher in patients with low hematocrit levels (\33 or 35 %) as compared to those with normal hematocrit levels [11, 29, 34, 35] . However, in the current study, hematocrit levels did not have any significant influence on tacrolimus CL/F. This discrepancy might be because there were a few patients with low hematocrit levels in our study (only 12 patients have lower hematocrit levels than 35 %). Xue et al. [36] reported no effects of hematocrit on tacrolimus clearance in healthy volunteers with normal hematocrit levels, which is consistent with our results.
Conclusions
ABCC2 haplotype as well as CYP3A5 polymorphism have significant impacts on the pharmacokinetics of tacrolimus. These findings suggest that MRP2 is involved in the efflux of tacrolimus or its metabolites into the lumen in cooperation with CYP3A in the small intestine. Determination of ABCC2 as well as CYP3A5 genotype may be useful for more accurate tacrolimus dosage adjustment.
